BASKHANBIOPharma Inc.

BASKHANBIOPharma Inc.

KKRX:354390
3,555.00
KRW
-40.00
(-1.11%)
679.15EPS
7.04P/E
33.55BMarket Cap
BASKHANBIOPharma Inc.
KRX:354390
(Korea Stock Exchange)

Recent

price

3,555.00

P/E

ratio

7.04

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
KRW
3,260.02
3,443.19
3,835.71
4,336.09
4,115.18
4,776.19
Revenue per Share
-51
55
24
396
399
679.15
Basic EPS, GAAP
-792.09
-543.46
-410.65
96.38
386.53
479.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
2,686.62
3,457.1
3,513.1
3,906.18
4,303.71
5,149.39
Book Value per Share
1,993.61
2,793.93
2,851.53
3,280.62
3,727.45
4,602.41
Tangible Book Value per Share
6
7
7
7
7
7
Basic Weighted Avg Shares
19,766
23,129
26,798
30,423
28,852
33,520
Sales/Revenue/Turnover
-3.47
1.81
0.97
3.99
4.31
8.64
Operating Margin (%)
1,117
1,436
1,623
2,103
2,053
1,901
Depreciation Expense
-309
369
168
2,778
2,797
4,766
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1.56
1.6
0.63
9.13
9.7
14.22
Profit Margin (%)
7,676
12,581
9,701
12,353
16,731
21,144
Working Capital
5
356
164
9
73
82
LT Debt
18,855
24,263
24,656
27,415
30,205
36,140
Total Equity
- -
1.82
1.05
- -
- -
- -
Return on Invested Capital (%)
- -
1.85
0.87
- -
- -
- -
Return on Capital (%)
- -
1.71
0.69
10.67
9.71
14.37
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

KRW

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.26%
19.65%
Free Cash Flow
- -
31.17%
24.06%
Net Income, GAAP
- -
270.81%
70.39%
Sales/Revenue/Turnover
- -
11.49%
16.18%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
30,423
2024
- -
- -
- -
- -
28,852
2025
- -
- -
- -
- -
33,520

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
396
2024
- -
- -
- -
- -
399
2025
- -
- -
- -
- -
679.15

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
BASKHANBIOPharma Inc. is a South Korea-based biopharmaceutical and healthcare company primarily engaged in the research, development, manufacturing, and distribution of pharmaceuticals, health functional foods, and specialized healthcare solutions. The company operates through core business segments comprising prescription pharmaceuticals (ETC), over-the-counter (OTC) medications, dietary supplements, and third-party contract manufacturing. Its product and service portfolio includes cardiovascular and circulatory system treatments; metabolic disorder therapies; gastrointestinal agents; central nervous system and neurological medications; musculoskeletal, analgesic, and anti-inflammatory drugs; respiratory and anti-infective formulations; health functional foods and dietary supplements designed for immune health, gut vitality, and nutritional support; specialized cosmeceutical and dermatological products; and comprehensive OEM, ODM, and contract development and manufacturing organization (CDMO) services. BASKHANBIOPharma markets and supplies its offerings to hospitals, specialty clinics, retail pharmacies, and healthcare distributors across South Korea and select international markets. In recent strategic developments, the company executed a corporate rebranding and reorganization to BASKHANBIOPharma Inc. to accelerate its expansion into advanced biopharmaceuticals and integrated healthcare products. Furthermore, the company upgraded its Good Manufacturing Practice (GMP)-certified production facilities to increase contract manufacturing capacity, entered into domestic co-promotion and distribution agreements to broaden market access, and initiated new development programs focused on enhanced drug delivery technologies and high-potency functional nutrition formulations. BASKHANBIOPharma Inc. was founded in 2019 and is headquartered in Seoul, South Korea.